[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DOP2016000299A - Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1 - Google Patents

Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1

Info

Publication number
DOP2016000299A
DOP2016000299A DO2016000299A DO2016000299A DOP2016000299A DO P2016000299 A DOP2016000299 A DO P2016000299A DO 2016000299 A DO2016000299 A DO 2016000299A DO 2016000299 A DO2016000299 A DO 2016000299A DO P2016000299 A DOP2016000299 A DO P2016000299A
Authority
DO
Dominican Republic
Prior art keywords
pirrolidine
pharmaceutical compositions
ido1 inhibitors
formula
relates
Prior art date
Application number
DO2016000299A
Other languages
English (en)
Inventor
Stefano Crosignani
Sandra Cauwenberghs
Gregory Driessens
Frederik DEROOSE
Original Assignee
Iteos Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from BE2014/0754A external-priority patent/BE1021251B1/fr
Application filed by Iteos Therapeutics filed Critical Iteos Therapeutics
Publication of DOP2016000299A publication Critical patent/DOP2016000299A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • C07D207/408—Radicals containing only hydrogen and carbon atoms attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere al compuesto de la fórmula I o sus enantiómeros, sales, solvatos o profármacos farmacéuticamente aceptables. La invención también se refiere al uso de los compuestos de la fórmula I como inhibidores de IDO1. La invención también se refiere al uso de los compuestos de la fórmula I para el tratamiento y/o la prevención de cáncer y endometriosis. La invención también se refiere a un proceso para preparar los compuestos de la fórmula I.
DO2016000299A 2014-05-15 2016-11-15 Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1 DOP2016000299A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461996976P 2014-05-15 2014-05-15
EP14168534 2014-05-15
BE2014/0754A BE1021251B1 (fr) 2014-05-15 2014-10-21 Derives de pyrrolidine-2,5-dione, compositions pharmaceutiques et methodes d'utilisation comme inhibiteurs de ido1

Publications (1)

Publication Number Publication Date
DOP2016000299A true DOP2016000299A (es) 2017-03-15

Family

ID=54479389

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2016000299A DOP2016000299A (es) 2014-05-15 2016-11-15 Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1

Country Status (20)

Country Link
US (3) US9603836B2 (es)
EP (1) EP3148531A1 (es)
JP (1) JP6231226B2 (es)
KR (1) KR101873672B1 (es)
CN (1) CN106536480B (es)
AP (1) AP2016009527A0 (es)
AU (1) AU2015260826B2 (es)
CA (1) CA2948842C (es)
CU (1) CU20160162A7 (es)
DO (1) DOP2016000299A (es)
EA (1) EA201650031A1 (es)
IL (1) IL248915A0 (es)
MD (1) MD20160118A2 (es)
MX (1) MX2016015005A (es)
PE (1) PE20170247A1 (es)
SG (1) SG11201608708WA (es)
TN (1) TN2016000501A1 (es)
TW (1) TWI567059B (es)
UY (1) UY36122A (es)
WO (1) WO2015173764A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
CN106536480B (zh) 2014-05-15 2019-09-03 艾特奥斯治疗公司 吡咯烷-2,5-二酮衍生物、药物组合物及用作ido1抑制剂的方法
CA2979616C (en) 2015-03-17 2020-04-28 Pfizer Inc. Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use
CA2929850A1 (en) * 2015-05-14 2016-11-14 Pfizer Inc. Combination therapies comprising a pyrrolidine-2,5-dione ido1 inhibitor
ES2889906T3 (es) 2015-05-21 2022-01-14 Harpoon Therapeutics Inc Proteínas de unión triespecíficas y usos médicos
WO2017025868A1 (en) 2015-08-10 2017-02-16 Pfizer Inc. 3-indol substituted derivatives, pharmaceutical compositions and methods for use
MX2018008797A (es) 2016-01-19 2018-11-29 Pfizer Vacunas contra el cancer.
JP2019507773A (ja) * 2016-03-09 2019-03-22 ネザーランズ トランスレーショナル リサーチ センター ビー．ブイ． インドールアミン２，３−ジオキシゲナーゼの阻害剤
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CN109952300B (zh) 2016-09-24 2022-01-18 百济神州有限公司 5或8-取代的咪唑并[1,5-a]吡啶
WO2018089301A1 (en) * 2016-11-08 2018-05-17 The Johns Hopkins University Pharmaceutical treatments for preventing or treating pancreatic cancer
EP3570832A4 (en) 2017-01-17 2020-06-10 Board Of Regents, The University Of Texas System NOVEL COMPOUNDS USEFUL AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND / OR TRYPTOPHANE DIOXYGENASE
WO2018209298A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Mesothelin binding proteins
AU2018277559A1 (en) 2017-05-30 2019-10-17 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-LAG-3 antibody, a PD-1 pathway inhibitor, and an immunotherapeutic agent
SG11202000197PA (en) 2017-07-11 2020-02-27 Pfizer Immunogenic compositions comprising cea muc1 and tert
CN110997682A (zh) 2017-08-17 2020-04-10 爱杜西亚药品有限公司 吲哚胺2,3-二氧酶及/或色氨酸2,3-二氧酶的抑制剂
EP3676263B1 (en) 2017-09-01 2021-10-06 Netherlands Translational Research Center B.V. 3-hydroxy-imidazolidin-4-one compounds as inhibitors of indoleamine 2,3-dioxygenase
KR20220111743A (ko) 2017-10-13 2022-08-09 하푼 테라퓨틱스, 인크. B 세포 성숙화 항원 결합 단백질
CA3087807A1 (en) 2018-01-15 2019-07-18 Idorsia Pharmaceuticals Ltd Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
WO2020018670A1 (en) 2018-07-17 2020-01-23 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
BE1026615B1 (fr) 2018-09-27 2020-07-06 Iteos Therapeutics S A Combinaison d’un inhibiteur du récepteur a2a et d'un agent anticancéreux
AU2019337974A1 (en) 2018-09-11 2021-04-08 iTeos Belgium SA Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
US11376255B2 (en) 2018-09-11 2022-07-05 iTeos Belgium SA Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
EP3856771A4 (en) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
US20220259212A1 (en) 2019-07-11 2022-08-18 Idorsia Pharmaceuticals Ltd Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
AR122421A1 (es) 2020-04-16 2022-09-07 iTeos Belgium SA Métodos y formulaciones para la administración de inhibidores a2a derivados de tiocarbamato
AU2021306613A1 (en) 2020-07-07 2023-02-02 BioNTech SE Therapeutic RNA for HPV-positive cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
EP4294948A1 (en) 2021-02-17 2023-12-27 iTeos Belgium SA Compounds, compositions and methods of treatment thereof
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
BR112023017582A2 (pt) 2021-03-05 2023-12-05 Univ Basel Composições para o tratamento de doenças ou condições associadas ao ebv
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
AU2023230110A1 (en) 2022-03-08 2024-10-24 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to increase t cell availability
WO2024126457A1 (en) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509731C2 (sv) 1996-05-14 1999-03-01 Labwell Ab Metod för palladium-katalyserade organiska reaktioner innefattande ett uppvärmningssteg utfört med mikrovågsenergi
JP2000095759A (ja) 1998-07-21 2000-04-04 Takeda Chem Ind Ltd 三環性化合物、その製造法および剤
US6265403B1 (en) 1999-01-20 2001-07-24 Merck & Co., Inc. Angiogenesis inhibitors
MXPA04002070A (es) 2001-09-19 2004-06-07 Pharmacia Corp Compuestos de indazol sustituidos para el tratamiento de la inflamacion.
IL164082A0 (en) 2002-03-28 2005-12-18 Eisai Co Ltd Azaindole derivatives and pharmaceutical compositions containing the same
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
FR2845996A1 (fr) 2002-10-16 2004-04-23 Servier Lab Nouveaux derives de[3,4-a:3,4-c]carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN101265254A (zh) 2003-03-27 2008-09-17 兰肯瑙医学研究所 新型ido抑制剂及其使用方法
FR2862647B1 (fr) 2003-11-25 2008-07-04 Aventis Pharma Sa Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
GB0328909D0 (en) 2003-12-12 2004-01-14 Syngenta Participations Ag Chemical compounds
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
NZ560225A (en) * 2005-02-09 2010-10-29 Arqule Inc Maleimide derivatives, pharmaceutical compositions and methods for treatment of cancer
WO2007039580A1 (en) 2005-10-05 2007-04-12 Nycomed Gmbh Imidazolyl-substituted benzophenone compounds
WO2007045622A1 (en) 2005-10-18 2007-04-26 Nycomed Gmbh Oxazolo [4 , 5-b] pyridine compounds as nitric oxide synthase inhibitors
WO2007050963A1 (en) 2005-10-27 2007-05-03 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use thereof
WO2007087488A2 (en) 2006-01-24 2007-08-02 Eli Lilly And Company Indole sulfonamide modulators of progesterone receptors
JP5255559B2 (ja) 2006-03-31 2013-08-07 アボット・ラボラトリーズ インダゾール化合物
AU2007240548A1 (en) 2006-04-05 2007-11-01 Novartis Ag Combinations of therapeutic agents for treating cancer
GB0624308D0 (en) 2006-12-05 2007-01-17 Molmed Spa Combination product
CN101595093A (zh) 2006-12-07 2009-12-02 诺瓦提斯公司 有机化合物
JP2010518014A (ja) 2007-01-31 2010-05-27 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用な２−アミノピリジン誘導体
US8389568B2 (en) 2007-03-16 2013-03-05 Lankenau Institute For Medical Research IDO inhibitors and methods of use thereof
CA2694224A1 (en) 2007-07-25 2009-01-29 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7868001B2 (en) 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
AU2008331480A1 (en) 2007-11-30 2009-06-11 Glaxosmithkline Llc Prolyl hydroxylase inhibitors
WO2009118292A1 (en) 2008-03-24 2009-10-01 Novartis Ag Arylsulfonamide-based matrix metalloprotease inhibitors
US20110159017A1 (en) 2008-04-11 2011-06-30 Ludwig Institute For Cancer Research Ltd. Trytophan catabolism in cancer treatment and diagnosis
DE102008052943A1 (de) 2008-10-23 2010-04-29 Merck Patent Gmbh Azaindolderivate
BRPI0922565A2 (pt) 2008-12-19 2015-12-15 Bristol Myers Squibb Co compostos de carbazol carboxamida úteis como inibidores de cinase
JP2012518011A (ja) 2009-02-17 2012-08-09 バーテックス ファーマシューティカルズ インコーポレイテッド ホスファチジルイノシトール３−キナーゼのテトラヒドロチアゾロピリジン阻害剤
SG182247A1 (en) 2009-05-27 2012-08-30 Hoffmann La Roche Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
KR101256018B1 (ko) 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
WO2011038163A1 (en) * 2009-09-23 2011-03-31 Medivation Technologies, Inc. Pyrido[3,4-b]indoles and methods of use
IN2012DN02679A (es) 2009-10-12 2015-09-04 Bayer Cropscience Ag
CA2777565C (en) 2009-10-13 2019-06-18 Ligand Pharmaceuticals Inc. Hematopoietic growth factor mimetic diphenylamine small molecule compounds and their uses
WO2012068406A2 (en) 2010-11-18 2012-05-24 Ligand Pharmaceuticals Incorporated Use of hematopoietic growth factor mimetics
AU2012230890A1 (en) 2011-03-22 2013-09-26 Amgen Inc. Azole compounds as Pim inhibitors
EP2714677B1 (en) 2011-05-23 2018-08-22 Merck Patent GmbH Pyridine-and pyrazine derivatives
CA2844799A1 (en) 2011-08-17 2013-02-21 Amgen Inc. Heteroaryl sodium channel inhibitors
US20160263087A1 (en) 2013-11-08 2016-09-15 Iteos Therapeutics Novel 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
US9126984B2 (en) 2013-11-08 2015-09-08 Iteos Therapeutics 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
WO2015121812A1 (en) 2014-02-12 2015-08-20 Iteos Therapeutics Novel 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use
WO2015140717A1 (en) 2014-03-18 2015-09-24 Iteos Therapeutics Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use
US20150266857A1 (en) 2014-03-18 2015-09-24 Iteos Therapeutics Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use
CN106536480B (zh) 2014-05-15 2019-09-03 艾特奥斯治疗公司 吡咯烷-2,5-二酮衍生物、药物组合物及用作ido1抑制剂的方法

Also Published As

Publication number Publication date
KR101873672B1 (ko) 2018-07-02
EP3148531A1 (en) 2017-04-05
WO2015173764A1 (en) 2015-11-19
US9603836B2 (en) 2017-03-28
US20150329525A1 (en) 2015-11-19
UY36122A (es) 2016-01-08
IL248915A0 (en) 2017-01-31
CN106536480B (zh) 2019-09-03
JP6231226B2 (ja) 2017-11-15
TW201605794A (zh) 2016-02-16
US9949951B2 (en) 2018-04-24
EA201650031A1 (ru) 2017-06-30
US10398679B2 (en) 2019-09-03
CN106536480A8 (zh) 2017-06-30
CA2948842A1 (en) 2015-11-19
AU2015260826B2 (en) 2019-10-24
US20180214415A1 (en) 2018-08-02
SG11201608708WA (en) 2016-11-29
TN2016000501A1 (en) 2018-04-04
CA2948842C (en) 2019-09-24
AU2015260826A1 (en) 2016-11-03
JP2017515850A (ja) 2017-06-15
CU20160162A7 (es) 2017-03-03
KR20160146807A (ko) 2016-12-21
US20170035731A1 (en) 2017-02-09
AP2016009527A0 (en) 2016-10-31
MD20160118A2 (ro) 2017-04-30
MX2016015005A (es) 2017-09-28
PE20170247A1 (es) 2017-03-29
CN106536480A (zh) 2017-03-22
TWI567059B (zh) 2017-01-21

Similar Documents

Publication Publication Date Title
DOP2016000299A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1
DOP2015000158A (es) Inhibidores de prmt5 y sus usos
DOP2017000151A (es) Derivados de quinazolina utilizados para tratar el vih
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
UY37900A (es) Nuevos derivados de rapamicina
CO2017006962A2 (es) Derivados de 2-anilinopirimidina sustituida como moudladores de egfr
CL2016001790A1 (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2.
CO2017000362A2 (es) Compuestos de derivados heterocíclicos sustituidos como inhibidores de demtilasa-1 específica lisina
CU24517B1 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
UY36244A (es) Derivados de la pirimidinona como inhibidores del factor xia y/o de la calicreína plasmática y composiciones farmacéuticas que los contienen
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
UY35951A (es) HETEROARILOS y USOS DE ESTOS
EA201992183A2 (ru) Синтез полициклических карбамоилпиридоновых соединений
NZ726608A (en) Phosphatidylinositol 3-kinase inhibitors
NZ726360A (en) Phosphatidylinositol 3-kinase inhibitors
NZ726638A (en) Phosphatidylinositol 3-kinase inhibitors
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
MX2018001992A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
CR20170496A (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
CL2018003121A1 (es) Inhibidores del potenciador del homólogo zeste 2.
CO2017000011A2 (es) Derivados de quinolizinona como inhibidores de pi3k
UY36758A (es) Inhibidores del potenciador del homólogo zeste 2
TR201819805T4 (tr) Flavaglin türevleri̇.